Loading
The enzyme that makes DNA building blocks from RNA building blocks. Gemcitabine's active form shuts it down and hydroxyurea quenches its catalytic radical, starving dividing cells of the nucleotides they need. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Large catalytic subunit of ribonucleotide reductase; target of gemcitabine diphosphate, with the small subunit RRM2 quenched by hydroxyurea.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Housekeeping enzyme present in every dividing cell (DNA building-block synthesis); not a selection marker, which is why these drugs are given by cancer type rather than by test. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Ribonucleotide reductase" OR ABSTRACT:"Ribonucleotide reductase" OR TITLE:"RRM1" OR ABSTRACT:"RRM1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ribonucleotide reductase (RRM1), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rrm1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rrm1.json. Licence CC BY-NC 4.0.